Protocol Ledger

NCT07707687 · Phase II · RECRUITING

Safety and Efficacy of Eculizumab in High-risk TA-TMA

Interventional Phase II clinical trial protocol NCT07707687 sponsored by First Affiliated Hospital of Zhejiang University in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-07-10 Enrollment: 24 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07707687
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)24 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07707687
Protocol FieldVerified Registry Value
NCT IdentifierNCT07707687
Consolidated Lead SponsorFirst Affiliated Hospital of Zhejiang University
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment24 participants (ESTIMATED)
Registered Start Date2026-07-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI